Drugs / rMenB+OMV NZ
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02106390 | Jun 2014 → Oct 2016 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rMenB+OMV NZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02106390 ↗ |
| Known as | Meningococcal group B Vaccine | “Meningococcal group B Vaccine, rMenB+OMV NZ” NCT02106390 ↗ |
| Modality | Vaccine | “Meningococcal group B Vaccine, rMenB+OMV NZ” NCT02106390 ↗ |